The neuromuscular activity of *Micrurus pyrrhocryptus* venom and its neutralization by commercial and specific coral snake antivenoms

Thiago Magalhães Camargo, Adolfo Rafael de Roodt, Maria Alice da Cruz-Höfling, Léa Rodrigues-Simioni

α, Department of Pharmacology, Faculty of Medical Sciences, University of Campinas (Unicamp), P.O. Box 6111, 13083-970, Campinas, SP, Brazil, β, Instituto Nacional de Produção de Biológicos, Administración Nacional de Laboratorios e Institutos de Salud (A.N.L.I.S.) “Dr. Carlos G. Malbrán”, Ministerio de Salud, Av. Vélez Sarsfield 563, CP 1281, Buenos Aires, Argentina, λ, Department of Histology and Embryology, Institute of Biology, University of Campinas (Unicamp), P.O. Box 6109, 13083-970, Campinas, SP, Brazil

*Correspondence to: Léa Rodrigues-Simioni, Email: simioni@unicamp.br, Tel: +55 19 35219533, FAX: +55 19 32892968

Received 27 May 2011; Accepted 21 June 2011; Published 24 June 2011

© Copyright The Author(s): Published by Library Publishing Media. This is an open access article, published under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5). This license permits non-commercial use, distribution and reproduction of the article, provided the original work is appropriately acknowledged with correct citation details.

**ABSTRACT**

The neuromuscular activity of *Micrurus pyrrhocryptus* venom was studied in chick biventer cervicis (BC) and mouse phrenic nerve-diaphragm (PND) preparations. The venom (0.5-50μg/ml) caused irreversible, time- and concentration-dependent blockade, with BC being more sensitive than PND (50% blockade with 10μg/ml in 22±3min and 62±4min, respectively; mean±SEM, n=6; p<0.05). In BC preparations, venom (0.5μg/ml) progressively abolished ACh-induced contractures, whereas contractures to exogenous KCl and muscle twitches in curarized preparations were unaffected. The venom neither altered creatine kinase release (venom: 25.8±1.75IU/l vs control: 24.3±2.2IU/l, n=6, after 120min), nor it caused significant muscle damage (50μg of venom/ml vs control: 3.5±0.8% vs 1.1±0.7% for PND; 4.3±1.5% vs 1.2±0.5% for BC, n=5). The venom had low PLA₂ activity. Neurotoxicity was effectively neutralized by commercial *Micrurus* antivenom and specific antivenom. These findings indicate that *M. pyrrhocryptus* venom acts postsynaptically on nicotinic receptors, with no significant myotoxicity.

**KEYWORDS:** Coral snake venom, neuromuscular blockade, neurotoxin, nicotinic receptor, postsynaptic

**INTRODUCTION**

Coral snakes constitute a large taxonomic group of more than 120 species and subspecies divided into three genera, *Leptomicrurus*, *Micruroides* and *Micrurus*, with a distribution ranging from the United States to Argentina (Scrochi, 1990; Roze, 1996; da Silva and Sites, 1999; da Silva and Sites, 2001).

*Micrurus* venoms are highly-neurotoxic, with clinical manifestations of palpebral ptosis, ophthalmoplegia and respiratory paralysis (in severe cases), indicating neuromuscular blockade (Vital Brazil and Vieira, 1996; da Silva and Bucaretchi, 2003; Warrell, 2004; Bucaretchi et al, 2006; Manock et al, 2008). Experimental studies have shown that the neuromuscular blockade is caused by pre- and postsynaptic neurotoxins from these venoms (Vital Brazil et al, 1976; Vital Brazil et al, 1977; Vital Brazil, 1980; Goularte et al, 1995; Vital Brazil et al, 1995; Serafim et al, 2002; Abreu et al, 2008). However, only a few of these toxins have actually been purified and studied in vivo and in vitro (Alapé-Girón et al, 1996b; Francis et al, 1997; Dal Belo et al, 2005), primarily because of the difficulty in maintaining these snakes in captivity (Serapicos and Merusse, 2002; Oliveira et al, 2005) and their low venom yields (de Roodt et al, 1998).

Although bites by *Micrurus* spp. in South America are relatively rare, severe cases of respiratory paralysis can be life-threatening if adequate therapeutic interventions are not implemented. Antivenom administration is the only specific treatment for coral snake bites, although ancillary measures, such as, mechanical ventilation and the administration of cholinesterase inhibitors (the latter...
M. pyrrhocryptus, which occurs in central Argentina, Bolivia, Paraguay and Brazil (in the states of Mato Grosso and Mato Grosso do Sul), was originally a subspecies of *Micrurus frontalis,* but was elevated to species status based on morphological features that distinguished it from *M. frontalis* (da Silva and Sites, 1999; Ministerio de Salud, 2007). Little is known about the composition of *M. pyrrhocryptus* venom (Hoge and Lancini, 1959; de Roodt 2002; Dokmetjian et al, 2009) and its neutralization by antivenom.

In this work, we studied the effects of *M. pyrrhocryptus* venom on neuromuscular transmission in avian and mammalian neuromuscular preparations, and examined the neutralization of neurotoxicity by commercial antivenom and specific antiserum.

**MATERIAL AND METHODS**

**Animals**

Adult male Swiss white mice (28-35gm) were supplied by the Multidisciplinary Center for Biological investigation (Cemib) at Unicamp. HY Line chicks (4-10 days old) were obtained from Globo Aves (Jaguariúna, SP, Brazil). The animals were housed at 24°C with free access to food and water. The experiments were done in accordance with the guidelines of the Brazilian College for Animal Experimentation (Cobea) and were approved by the institutional Ethics Committee on Animal Use (CEUA/Unicamp, Protocol No. 1550-1).

**Venom, antivenoms and venom neutralization**

*M. pyrrhocryptus* venom, obtained from snakes captured in Santiago del Estero, Argentina, and specific antivenin were gifts from Dr Alejandro U Vogt (The Centro Zootoxicológico de Misiones, Argentina). The specific antivenin (SAV, batch 115) was raised in horses by the Instituto Nacional de Producción de Biológicos (Instituto de Salud de Misiones, Argentina). The specific antivenom (SAV, Batch No. 1550-1). was obtained from the Instituto Butantan (São Paulo, SP, Brazil). Commercial antivenom (Batch No. 03.2184), produced by immunizing the venom immunogen of this antivenom. Commercial antivenoms and venom neutralization

**Chick biventer cervicis preparation**

Biventer cervicis muscles obtained from chicks previously anesthetized with halothane were mounted as previously described (Ginsborg and Warriner, 1960). The preparations were suspended under a resting tension of 1gm in 5ml of Krebs solution of the following composition: 136mM NaCl, 5mM KCl, 2.5mM CaCl₂, 2.8mM NaHCO₃, 1.2mM MgSO₄, 1.2mM KH₂PO₄ and 11mM glucose), maintained at 37°C or 22°C (the latter used to verify the involvement of venom PLA₂ activity in neuromuscular blockade) and aerated with a mixture of 95%, v/v, O₂, 5%, v/v, CO₂. The preparations were stimulated indirectly with supramaximal pulses (6V, 0.2ms and 0.1Hz) delivered by a Grass S4 electronic stimulator (Grass Instrument Co, Quincy, MA, USA) and were allowed to stabilize for at least 15min before the addition of drugs, venom or venom:antivenom mixtures. In some experiments, the muscle contractures to exogenous carbachol (carbamylcholine + CCh, 8µM), acetylcholine (ACH, 110µM) and KCl (20mM) were obtained before and after incubation of the tissues with venom. In order to determine the kinetics of ACh contracture inhibition, preparations under indirect stimulation and incubated with a single venom dose (0.5µg/ml) were assayed in different time points (5, 10, 15 and 30min) (n=5-10 preparations per time interval).

**Mouse phrenic-nerve diaphragm muscle preparation**

Whole diaphragms along with the phrenic nerves were removed from mice anesthetized with isoflurane and sacrificed by exsanguination. The left diaphragm was mounted essentially as described for rats (Bülbring, 1946). The preparation was suspended under a constant tension of 5gm in a 5ml organ bath containing aerated (95%, v/v, O₂, 5%, v/v, CO₂) Tyrode solution (pH 7.4, 37°C) of the following composition: 137mM NaCl, 2.7mM KCl, 1.8mM CaCl₂, 0.49mM MgCl₂, 0.42mM NaHPO₄, 11.9mM NaHCO₃, and 11.1mM glucose. In some experiments, CaCl₂ was replaced by 4mM SrCl₂, to assess the influence of venom PLA₂ activity on the venom-induced neuromuscular blockade. Supramaximal pulses (0.1Hz, 0.2ms, 3-6V) and tetanic stimuli (50Hz, 0.2ms) delivered by a Grass S4 stimulator were applied by electrodes placed on the motor nerve. Isometric muscle tension was recorded using a Load Cell BG 50gm force-displacement transducer (Kulite Semiconductor Products Inc., Leonia, NJ, USA) coupled to a physiograph (Gould RS 3400, Cleveland, OH, USA). The preparations were allowed to stabilize for at least 20min before the addition of drugs or venom.

**Reversal of neuromuscular blockade by neostigmine, 3,4-diaminopyridine and washing**

The reversibility of the venom-induced blockade was assessed by incubating the preparations with neostigmine (10µg/ml) or 3,4-diaminopyridine (10µg/ml), or by extensive washing, after 50% neuromuscular blockade had been achieved.

**PLA₂ activity**

Venom PLA₂ activity was assayed in 10mM Tris-HCl, pH 8.0, containing 10mM CaCl₂, essentially as described elsewhere (Abreu et al, 2008). The assays were done in triplicate, and the activity expressed as the increase in absorbance at 425nm measured in a multiwell plate reader for postsynaptically-active venoms), can also be useful (Coelho et al, 1992; Vital Brazil and Vieira, 1996; Bucaretechi et al, 2006). Experimentally, the neutralizing capacity of antivenins against neurotoxins is frequently studied in neuromuscular preparations in vitro, following pre-incubation of venom with antivenom (Barfaraz and Harvey, 1994; Alapé-Girón et al, 1996a; Alapé-Girón et al, 1997; Hodgson and Wickramaratna, 2002; Abreu et al, 2008).

The neutralizing capacity of the antivenins was studied by pre-incubating venom (10µg/ml) with each antivenin for 30min at 37°C, at a venom:antivenin ratio of 1.5mg of venom:1.0ml of antivenin, before adding to the organ bath.
(SpectraMax 340, Molecular Devices, Sunnyvale, CA, USA). Venom from the South American rattlesnake, *Crotalus durissus terrificus*, was used as a positive control in this assay. *C. d. terrificus* venom was a gift from JC Cogo (Universidade do Vale do Paraíba, São José dos Campos, SP, Brazil).

**Creatine kinase (CK) activity**

Samples of organ bath solution (100μl) were collected before and after a 120min incubation with venom (5μg/ml in BC preparations; CK release by PND preparations was not examined); the initial 100μl aliquot was replaced by fresh solution. The samples were stored at 4°C, and CK activity was assayed within 4hrs after the experiment, using a commercial kit (Sigma Chemical Co, St Louis, MO, USA). CK activity was also assayed in control experiments without venom. Enzyme activity was expressed in international units per liter (IU/l), with one unit of activity corresponding to the phosphorylation of 1nmol of creatine/min at 25°C.

**Light microscopy**

At the end of the experiments, when complete blockade had been achieved at venom concentrations of 5, 10 and 50μg/ml, chick BC and mouse PND preparations were immediately fixed in Bouin’s solution and processed for embedding in historesin. Sections 3-5 μm thick were stained with hematoxylin-eosin and examined by light microscopy, using an Olympus microscope (Olympus Optical Co Ltd, Tokyo, Japan) prior to photographing. Muscle damage was quantified by counting 50 fibers (normal or damaged) in four randomly chosen, non-overlapping fields (200 fibers/section) in one section from each of five tissues (experiments) per preparation (total of 1000 fibers each for BC and PND preparations). Similarly, 1000 fibers were counted from five control experiments for each preparation. The percentage of damaged fibers was calculated as (number of damaged fibers × total number of fibers) ×100.

**Statistical analysis**

The results were expressed as the mean ±SEM and were compared statistically using Student’s unpaired t-test or ANOVA for repeated measures. A value of *p* ≤ 0.05 indicated significance.

**RESULTS**

**Blockade of contractile responses**

*M. pyrrhocryptus* venom produced time- and concentration-dependent blockade of contractile responses in BC and PND preparations (Figure 1A and 1B), with the former preparations being more sensitive to blockade: At venom concentrations of 5μg/ml and 10μg/ml, the time...
for 50% neuromuscular blockade was 52±0.9min and 22±3min (n=6 each), respectively, in BC preparations; while in PND preparations, it was 110±2min and 62±4min (n=6 each), respectively. In contrast, there was no difference in sensitivity at the highest venom concentration (50μg/ml: 15.1±1.6min vs 18.8±2.3min for BC and PND preparations, respectively). Treatment with neostigmine (a cholinesterase inhibitor) and 3-4-diaminopyridine (a potassium channel blocker) produced a transient reversal after 50% of venom-induced neuromuscular blockade (n=6 each; data not shown), followed by complete irreversible blockade after 60min. This finding suggests that when only half of the endplates are affected by venom, some reversibility of blockade is viable.

The venom (1, 5, 10 and 50μg/ml) inhibited muscle contractions to exogenous acetylcholine (ACh, 110μM) and carbachol (CCh, 8μM) in BC preparations, but did not affect the responses to KCl (20mM) (Figure 1C and 1D).

**Tetanic responses in mouse phrenic-nerve diaphragm preparations**

In PND preparations exposed to tetanic stimuli (70Hz, 0.2ms), followed by incubation with venom (10μg/ml, n=6), there was a progressive, time-dependent decrease in the amplitude of the responses (Figure 2A and 2B) more similar to that seen with α-bungarotoxin (a non-depolarizing toxin, 10μg/ml, n=6) than with succinylcholine (a depolarizing agent, 10μg/ml, n=6; data not shown).

**Kinetics of inhibition of responses to exogenous acetylcholine**
The incubation of BC preparations with a low venom concentration (0.5μg/ml) for up to 30min resulted in progressive inhibition of the contractile response to exogenous ACh (Figure 3). This finding suggested that the venom contained components that interacted with postsynaptic nicotinic receptors.

**Effect of venom on directly stimulated preparations**
Incubation with venom (10μg/ml) did not significantly affect muscle twitches of curarized (d-tubocurarine, 3μM), directly stimulated PND preparations (Figure 4).

**PLA₂ activity**
The PLA₂ activity of *M. pyrrhocryptus* venom was 0.09±0.04U/mg, approximately one-third that of *C. d. terrificus* (South American rattlesnake) venom (0.30±0.07U/mg; n=6 each, p<0.05). To examine whether this PLA₂ activity could contribute to the venom-induced neuromuscular blockade, experiments were done at 22°C (BC preparations) or Ca²⁺ (1.8mM) was replaced by Sr²⁺ (4.0mM) (PND preparations) in order to inhibit PLA₂ activity. These interventions did not significantly affect the venom potency and time for neuromuscular blockade, indicating that PLA₂ activity was not involved or had only a minor role in the venom-induced blockade.

**Creatine kinase (CK) release**
Incubation with *M. pyrrhocryptus* venom (5μg/ml) for up to 120min did not significantly alter the release of CK by BC preparations when comparing with the corresponding controls (Figure 5).

**Light microscopy**
Histological analysis of control BC and PND preparations showed normal muscle morphology with little fiber damage (1.2±0.5% in BC and 1.1±0.7% in PND). Incubation with the venom (50μg/ml) did not significantly alter this basal damage (4.3±1.5% and 3.5±0.8% for BC and PND preparations, respectively; n=5 each in all cases).

**Neutralization by commercial *Micrurus* antivenom and specific antivenom**
Pre-incubation (30min at 37°C) of *M. pyrrhocryptus* venom (10μg/ml) with commercial *Micrurus* antivenom in the proportion recommended by the manufacturer, or with specific...
antivenom at a venom:antivenom ratio of 1.5mg of venom to 1.0ml of antivenom, totally abolished the venom-induced neuromuscular blockade in both preparations (Figure 6).

DISCUSSION

* Micrurus* venom caused irreversible, time- and concentration-dependent neuromuscular blockade of muscle twitches in BC and PND preparations, with the former preparations being more sensitive than the latter. The greater sensitivity of BC preparations was probably related to differences in the innervation of these two preparations, with avian muscle having both focally- and multiply-innervated fibers that can respond to electrical stimulation or exogenous nicotinic agonists (Vital Brazil, 1980; Hodgson and Wickramaratna, 2002). These findings agree with reports for other *Micrurus* venoms, such as *M. altirostris* (Abreu et al, 2008), *M. dumerilii carinicauda* (Serafim et al, 2002), *M. frontalis* (Vital Brazil et al, 1976; Vital Brazil and Vieira, 1996), *M. lemniscatus carvalhoi* (Cecchini et al, 2005), *M. nigrocinctus* (Goularte et al, 1995) and *M. spixii* (Vital Brazil et al, 1995).

The venom inhibited contractures to exogenous ACh and CCh, indicating a predominantly postsynaptic action through the blockade of cholinergic nicotinic receptors, as also suggested for other *Micrurus* venoms (Goularte et al, 1995; Serafim et al, 2002, Abreu et al, 2008). The time-dependent blockade of the responses to exogenous ACh shown in Figure 3 can only be properly understood when compared with Figure 1A, which shows venom-induced neuromuscular blockade in chick BC preparations. In Figure 3, a venom concentration of 0.5μg/ml produced complete blockade of the responses to exogenous ACh within 30min. In contrast, within a similar time frame of 30min, there was <10% blockade in indirectly stimulated preparations incubated with the double venom concentration (1μg/ml). These findings agree with the well-known existence of two populations of nicotinic receptors in BC preparations (Chang et al, 1973; Chang and Su, 1975). The ability of toxins to distinguish between these two receptor populations could be exploited to provide a simple, sensitive assay for screening neurotoxins and nicotinic cholinergic agonists.

The postsynaptic action of *M. pyrrhocryptus* venom was also indicated by the absence of fade in the tetanic response to indirect stimulation at 70Hz. This tetanic pattern was more similar to that produced by α-bungarotoxin (a non-depolarizing toxin) than by succinylcholine (a depolarizing agent) (Gallicci and Oliveira, 1994; Serra and Oliveira, 2006).

* Micrurus* venoms are rich in PLA2 (Aird and da Silva, 1991; da Silva and Aird, 2001; Cecchini et al, 2005; Tanaka et al, 2010) that may contribute to the biological activities of these venoms (Alapé-Girón et al, 1996b; Francis et al, 1997; Oliveira et al, 2008). As shown here, *M. pyrrhocryptus* venom had low activity when compared with that of *C. d. terrificus*. The finding that reducing the temperature of the experiment from 37°C to 22°C (Goularte et al, 1995; Rodrigues-Simioni et al, 2004) or the substitution of Ca2+ by Sr2+ (Rodrigues-Simioni et al, 1995; Ponce-Soto et al, 2009) to attenuate PLA2 activity did not significantly alter the neuromuscular blockade indicated that this enzymatic activity was not a major contributor to venom-induced blockade.
In contrast, the intramuscular injection of Micrurus venoms in mice and rats results in myotoxicity, seen morphologically and through an increase in serum CK levels (de Roodt AR, 2002). Myonecrosis has been also reported for several coral species (Gutiérrez et al, 1983; Gutiérrez et al, 1986, Gutiérrez et al, 1992; Goularte et al, 1995). These discrepant results may be related to the different animal models (in vitro vs in vivo) and the venom concentrations used.

Commercial Brazilian Micrurus antivenom raised against M. corallinus and M. frontalis venoms and specific antivenom effectively neutralized the neurotoxicity of M. pyrrhocryptus venom in vitro. This finding suggests that it is not necessary to include M. pyrrhocryptus venom in the pool of Micrurus venoms used for antivenom production. This conclusion differs from findings for M. altirostris, another species originally classified as a subspecies of M. frontalis, for which commercial Brazilian antivenom showed little neutralization of the lethality (Moraes et al, 2003) and neuromuscular activity (Abreu et al, 2008) of the venom. In fact, various studies have suggested the need to include additional Micrurus species in the pool of venoms used in immunization protocols in order to improve the neutralization capacity of commercial antivenoms (Higashi et al, 1995; de Roodt et al, 2004; Tanaka et al, 2010).

CONCLUSIONS

M. pyrrhocryptus venom produced neuromuscular blockade through a predominantly postsynaptic action that was effectively neutralized by commercial and specific antivenoms. The neutralization of neurotoxicity observed here suggests that these antivenoms may be useful in treating humans envenomed by this species.

ACKNOWLEDGMENTS

The authors thank Gildo B Leite and Marta B Leonardo for their excellent technical assistance, Miguel Silva and Marcos Silva for caring for the animals, and Dr Stephen Hyslop for suggestions to the text and language revision. This work was supported by grants from the State of São Paulo Research Foundation (Fapesp) and Teaching, Research and Extension Support Fund (Faepex-Unicamp). TMC was supported by an MSc scholarship from the National Council for Scientific and Technological Development (CNPq). MACH and LRS were supported by research fellowships from CNPq.

STATE OF COMPETING INTERESTS

None declared.

REFERENCES

Abreu VA, Leite GB, Oliveira CB, Hyslop S, Furtado MF and Rodrigues-Simioni L. 2008. Neurotoxicity of Micrurus altirostris (Uruguayan coral snake) venom and its neutralization by commercial coral snake antivenom and specific antiserum raised in rabbits. Clin Toxicol (Phila), 46, 519-527.

Aird SD and da Silva NJ Jr. 1991. Comparative enzymatic composition of Brazilian coral snake (Micrurus) venoms. Comp Biochem Physiol, 99B, 287-294.
Alape-Girón A, Miranda-Arrieta K, Cortes-Bratti X, Stiles BG and Gutiérrez JM. 1997. A comparison of in vitro methods for assessing the potency of therapeutic antivena against the venom of the coral snake *Micrurus nigrocinctus*. Toxicon, 35, 573-581.

Alape-Girón A, Stiles BG and Gutiérrez JM. 1996a. Antibody-mediated neutralization and binding-reversal studies on α-neurotoxins from *Micrurus nigrocinctus nigrocinctus* (coral snake) venom. Toxicon, 34, 369-380.

Alape-Girón A, Stiles B, Schmidt J, Girón-Cortes M, Theles- tam M, Hörnwall H and Bergman T. 1996b. Characterization of multiple nicotinic acetylcholine receptor-binding proteins and phospholipases A₁ from the venom of the coral snake *Micrurus nigrocinctus nigrocinctus*. FEBS Lett, 380, 29-32.

Barfaraz A and Harvey AL. 1994. The use of the chick biventer cervicus preparation to assess the protective activity of six international reference antivenoms on the neuromuscular effects of snake venoms *in vitro*. Toxicon, 32, 267-272.

Bucaretchi F, Hyslop S, Vieira RJ, Toledo AS, Madureira PR and de Capitani EM. 2006. Bites by coral snakes (*Micrurus spp.*) in Campinas, State of São Paulo, southeastern Brazil. Rev Inst Med Trop São Paulo, 48, 141-145.

Bülbring E. 1946. Observations on the isolated phrenic-nerve diaphragm preparation of the rat. Br J Pharmacol, 1, 38-56.

Cecchini AL, Marucusi S, Silveira LB et al. 2005. Biological and enzymatic activities of *Micrurus spumarius* snake venoms. Comp Biochem Physiol Part A, 140, 125-134.

Chang CC, Chen TF and Chuang ST. 1973. N,O-di and N,N,O-tri[3H]acetyl α-bungarotoxins as specific labeling agents of cholinergic receptors. Br J Pharmacol, 47, 147-160.

Chang CC and Su MJ. 1975. Further evidence that extrinsic acetylcholine acts preferentially on extrajunctional receptors in the chick biventer cervicus muscles. Eur J Pharmacol, 33, 337-344.

Chang CC, Jai Su M and Hsien Tung L. 1977. Appearance of new acetylcholine receptors on the baby chick biventer cervicus and denervated rat diaphragm muscles after blockade with α-bungarotoxin. J Physiol, 268, 449-465.

Coelho LK, Silva E, Esposito C and Zannin M. 1992. Clinical features and treatment of Elapidae bites: report of three cases. Human Exp Toxicol, 11, 135-137.

da Silva NJ Jr and Aird SD. 2001. Prey specificity, comparative lethality and compositional differences of coral snake venoms. Comp Biochem Physiol Physiol, 128, 425-456.

da Silva NJ Jr and Sites JW. 2001. Phylogeny of South American triad coral snakes (Elapidae: *Micrurus*) based on molecular characters. Herpetotologia, 57, 1-22.

da Silva NJ Jr and Bucaretchi F. 2003. Mecanismo de ação do veneno elapídico e aspectos clínicos dos acidentes. In: Cardoso JLC, França FOS, Wen FH, Malaque CMS, Haddad Jr V (Eds.), *Animais Poissons do Brasil*. Biologia, Clínica e Terapêutica dos Acidentes. São Paulo, Sarvier/FAPESP, pp. 99-107.

Dal Belo CA, Leite GB, Toyama MH et al. 2005. Pharmacological and structural characterization of a novel phospholipase A₁ from *Micrurus dumerili carinicauda* venom. Toxicon, 46, 736-750.

de Roodt AR, Dolab JA, Galarce PP et al. 1998. A study on the mammalian neuromuscular effects of snake venoms. *In vitro*. Toxicon, 32, 267-272.

dee Roodt AR, Dolab JA, Galarce PP et al. 2008. Phospholipases A₁ isolated from *Micrurus lemniscatus* coral snake venom: behavioral electroencephalographic, and neuropathological aspects. Brain Res Bull, 75, 629-639.

Gallacci M and Oliveira AC. 1994. Pre- and postsynaptic mechanisms involved in fade induced by panceruclid in the isolated rat muscle. Pharmacol, 49, 265-270.

Ginsborg BL and Warriner JN. 1960. The isolated chick *biventer cervicus* nerve muscle preparation. Br J Pharmacol, 15, 410-411.

Goularte FC, Cruz-Höfling MA, Cogo JC, Gutiérrez JM and Rodrigues-Simioni L. 1995. The ability of specific antivenom and low temperature to inhibit the myotoxicity and neuromuscular block induced by *Micrurus nigrocinctus* venom. Toxicon, 33, 679-689.

Gutiérrez JM, Arroyo O, Chaves F, Lomonte B and Cerdas L. 1986. Pathogenesis of myonecrosis induced by coral snake (*Micrurus nigrocinctus*) venom in mice. Br J Exp Pathol, 67, 1-12.

Gutiérrez JM, Lomonte B, Portilla E, Cerdas L and Rojas E. 1983. Local effects induced by coral snake venoms: evidence of myonecrosis after experimental inoculations of venoms from five species. Toxicon, 21, 777-783.

Gutiérrez JM, Rojas G, da Silva NJ Jr and Nuñez J. 1992. Experimental myonecrosis induced by the venoms of South American *Micrurus* (coral snakes). Toxicon, 30, 1299-1302.

Higashi H, Guidolini R, Caricati CP et al. 1995. Antigenic cross-reactivity among components of Brazilian Elapidae snake venoms. Braz J Med Biol Res, 28, 767-771.

Hodgson WC and Wickramaratna JC. 2002. *In vitro* neuromuscular activity of snake venoms. Clin Exp Pharmacol Physiol, 29, 807-814.

Hoge AR and Lancini AR. 1959. Note on *Micrurus surinamensis nattereri* Schmidt and *Micrurus pyrrochroicus* Cope. Mem Inst Butantan, 29, 9-13.

Manock SR, Suarez G, Graham D, Avila-Aguero ML and Warrell DA. 2008. Neurotoxic envenoming by South American coral snake (*Micrurus lemniscatus helleri*): case report from Eastern Ecuador and review. Trans R Soc Trop Med Hyg, 102, 1127-1132.

Ministerio de Salud. 2007. Guía de Prevención, Diagnóstico, Tratamiento y Vigilancia Epidemiológica de los Envenenamientos. Ministerio de Salud, Buenos Aires, 48 pp.

Moraes FV, Sousa-e-Silva MC, Barbaro KC, Leitão MA and Furdado MF. 2003. Biological and immunochemochemical characterization of *Micrurus alitoxis* venom and serum neutralization of its toxic activities. Toxicon, 41, 71-79.

Oliveira DA, Harasawa C, Seibert CS et al. 2008. Phospholipases A₁ isolated from *Micrurus lemniscatus* coral snake venom: behavioral electroencephalographic, and neuropathological aspects. Brain Res Bull, 75, 629-639.

Oliveira L, Almeida-Santos SM, Ribeiro da Costa AC, Roveri Scar-tozzi R, Germano VJ and Salomão MG. 2005. Manutenção de serpentes em cativeiro no Instituto Butantan: I-A longevidade do gênero Micrurus. Pap Avulsas Inst Pau Brasil, 8-9, 55-61.

Ponce-Soto LA, Barros IC, Hernandez S et al. 2009. Neuromuscular activity of BaTX, a presynaptic basic PLA₂, isolated Bothrops alternatus snake venom. Comp Biochem Physiol C Toxicol Pharmacol, 150, 291-297.

Rodrigues-Simioni L, Zamunér SR, Cogo JC et al. 2004. Pharmacological evidence for a presynaptic action of venoms from Bothrops insularis (jaraíca ilhoa) and Bothrops neuwiedi (jarai-aca pintada). Toxicon, 43, 633-638.

Rozzi JA. 1996. *Coral Snakes of the Americas*. Biology, Identification and Venoms. Struik Publishing Co, Malabar FL.

Scrochi GJ. 1990. El gênero Micrurus (Serpientes: Elapidae) en la República Argentina. Boll Musl Reg Sci Nat Torino, 8, 105-109.

Serra CSM and Oliveira AC. 2006. Cicatrizzazione: myographical and electrophysiological studies in the isolated rat muscle. Fund Clin Pharmacol, 20, 291-298.
Tanaka GD, Furtado MF, Portaro FC, SantAnna OA and Tambourgi DV. 2010. Diversity of Micrurus snake species related to their venom toxic effects and the prospective of antivenom neutralization. PLoS Negl Trop Dis, 4, e622.

Vital Brazil O. 1980. Venenos ofídicos neurotóxicos. Rev Ass Méd Brasil, 26, 212-218.

Vital Brazil O, Fontana MD and Pellegrini AF. 1976/77. Physiopathologie et thérapeutique de l’envenomation expérimentale causée para le venin de Micrurus frontalis. Mem Inst Butantan, 40/41, 221-240.

Vital Brazil O, Fontana MD, Heluany NF and Laure CJ. 1995. Mode of action of the coral snake Micurus spixii venom at the neuromuscular junction. J Nat Toxins, 4, 19-33.

Vital Brazil O and Vieira RJ. 1996. Neostigmine in the treatment of snake accidents caused by Micrurus frontalis: report of two cases. Rev Inst Med Trop, 38, 61-67.

Warrell DA. 2004. Snakebites in Central and South America: epidemiology, clinical features and clinical management. In: Campbell JA, Lamar WW (Eds.), Venomous Reptiles of the Western Hemisphere, Vol. 2. Comstock Publishing Associates/Cornell University Press, Ithaca, pp. 709-761.